Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schenker

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Cancers|March 10, 2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesManish A Shah, Anghel Adrian Udrea, Igor Bondarenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Lancet (London, England)|January 28, 2025
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThierry André, Elena Elez, Heinz-Josef Lenz, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Cancers|March 10, 2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesManish A Shah, Anghel Adrian Udrea, Igor Bondarenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Lancet (London, England)|January 28, 2025
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThierry André, Elena Elez, Heinz-Josef Lenz, et al.
Pageof 10